| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2005;45:385.)
© 2005 American Heart Association, Inc.
Original Articles |
From the Division of Clinical Pharmacology, Department of Medicine and Pharmacology, and the Autonomic Dysfunction Center, Vanderbilt University School of Medicine, Nashville, Tenn.
Correspondence to Italo Biaggioni, MD, 1500 21st Ave S, Suite 3500, Clinical Trials Center, Vanderbilt University, Nashville, TN 37212. E-mail Italo.biaggioni{at}vanderbilt.edu
Abstract
Postural tachycardia syndrome (POTS) is a disabling condition that commonly affects otherwise normal young females. Because these patients can present with a flushing disorder, we hypothesized that mast cell activation (MCA) can contribute to its pathogenesis. Here we describe POTS patients with MCA (MCA+POTS), diagnosed by episodes of flushing and abnormal increases in urine methylhistamine, and compared them to POTS patients with episodic flushing but normal urine methylhistamine and to normal healthy age-matched female controls. MCA+POTS patients were characterized by episodes of flushing, shortness of breath, headache, lightheadedness, excessive diuresis, and gastrointestinal symptoms such as diarrhea, nausea, and vomiting. Triggering events include long-term standing, exercise, premenstrual cycle, meals, and sexual intercourse. In addition, patients were disabled by orthostatic intolerance and a characteristic hyperadrenergic response to posture, with orthostatic tachycardia (from 79±4 to 114±6 bpm), increased systolic blood pressure on standing (from 117±5 to 126±7 mm Hg versus no change in POTS controls), increased systolic blood pressure at the end of phase II of the Valsalva maneuver (157±12 versus 117±9 in normal controls and 119±7 mm Hg in POTS; P=0.048), and an exaggerated phase IV blood pressure overshoot (50±10 versus 17±3 mm Hg in normal controls; P<0.05). In conclusion, MCA should be considered in patients with POTS presenting with flushing. These patients often present with a typical hyperadrenergic response, but ß-blockers should be used with great caution, if at all, and treatment directed against mast cell mediators may be required.
Key Words: autonomic nervous system norepinephrine tachycardia
This article has been cited by other articles:
![]() |
S. Carew, M. O. Connor, J. Cooke, R. Conway, C. Sheehy, A. Costelloe, and D. Lyons A review of postural orthostatic tachycardia syndrome Europace, January 1, 2009; 11(1): 18 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Brooks and L. A.P. Francis Postural orthostatic tachycardia syndrome: Dental treatment considerations J Am Dent Assoc, April 1, 2006; 137(4): 488 - 493. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Ziegler and D. P. Rizos The Causes of Postural Cardiovascular Disorders Hypertension, March 1, 2005; 45(3): 354 - 355. [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |